NTC 121

Drug Profile

NTC 121

Alternative Names: NTC-121

Latest Information Update: 08 Oct 2002

Price : $50

At a glance

  • Originator Neurotech SA
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 23 Aug 2002 Discontinued - Phase-II for Glioma in France (unspecified route)
  • 19 Dec 2000 NTC 121 is available for licensing (http://www.neurotech.fr)
  • 15 May 2000 Phase-II clinical trials for Glioma in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top